[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"xerostomia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:xerostomia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,47,74,102,123,151,171,196,225,246,274,294,313],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644717","evaluating-the-optimal-timing-of-acupuncture-for-managing-chemoradiation-induced-xerostomia-in-patients-with-head-and-neck-cancers-100644717",false,"NCT07674706","Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers","A Pilot Randomised Trial Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers","Inclusion Criteria:\n\nParticipants are eligible to be included in the study only if all the following criteria apply:\n\n1. Aged 21 years or older\n2. Oral cavity or oropharyngeal squamous cell carcinoma, or nasopharyngeal carcinoma planned for either curative adjuvant or definitive chemoradiotherapy using intensity-modulated radiation therapy (IMRT).\n\n   Participants who have received prior induction chemotherapy or are planned for adjuvant chemotherapy are not excluded.\n3. Anatomically intact parotid and submandibular glands\n4. Eastern Cooperative Oncology Group performance status of 0 to 2\n5. Able to provide informed consent\n6. A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies:\n\n   1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR\n   2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the acupuncture period and for at least 28 days after the last acupuncture.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n1. History of xerostomia, Sjögren's disease, or another underlying systemic illness known to cause xerostomia\n2. Prior head and neck radiation treatment\n3. Has bleeding disorders (e.g. Hemophilia), or on anticoagulants (e.g. warfarin, low molecular weight heparin and novel oral anticoagulants)\n4. Upper or lower extremity deformities that could interfere with accurate acupoint location or alter the energy pathway as defined by traditional acupuncture theory.\n5. Local skin infections, lymphedema, or severe skin conditions (e.g., psoriasis, eczema) at or near the acupuncture sites\n6. Ongoing active systemic infection\n7. Current use of amifostine or cholinergic agonist medications (pilocarpine, cevimeline) that can affect salivary functions (salivary substitute not prohibited, but if using, they must refrain from using it for at least 24 hours prior to salivary flow assessment)\n8. Concurrent use of alternative medicines (e.g., Chinese Propriety medicines), that could affect salivary function\n9. Is pregnant or expecting to conceive within the projected duration of the trial, starting with the screening visit through 28 days after the last acupuncture treatment\n10. Low body mass index, ie. BMI \\\u003C 15\n11. Mental incapacitation or significant emotional or psychiatric disorder that, in the opinion of the investigator, may prevent the patient from cooperating with trial procedures","ALL","21 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","While existing data supports the use of acupuncture to reduce radiation-induced xerostomia, the optimal timing of acupuncture for managing chemoradiation-induced xerostomia remains an area of active investigation. Prior studies have administered acupuncture either in patients who developed xerostomia 12 months after radiation 10 or during the radiation therapy itself 9. The hypothesis is that acupuncture may be more effective in preventing and reducing xerostomia when administered early during CRT, rather than after chronic xerostomia has already set in. Yet, oncologists have concerns about the potentially higher risk of complications, such as infection, associated with acupuncture, especially if administered concurrently with chemoradiotherapy. Therefore, this study aims to conduct this randomised trial to evaluate the impact of early versus delayed acupuncture on patient-reported and objective measures of xerostomia, as well as the safety and tolerability of acupuncture in this setting.\n\nTo our knowledge, this will be the first randomised clinical trial evaluating the optimal timing for incorporating acupuncture to reduce xerostomia in patients undergoing chemoradiation for head and neck cancers. It is also the first study conducted in Singapore to study the role of acupuncture in reducing CRT-induced xerostomia.",[26,27,28,29,30,31],"Xerostomia","Head Cancer","Neck Cancer","Nasopharyngeal Carcinoma (NPC)","Oral Cavity Squamous Cell Carcinoma","Oropharyngeal Squamous Cell Carcinoma",[33],"Acupuncture","NOT_YET_RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":20},"2026-06",{"date":42,"type":20},"2029-06",{"name":44,"class":45},"National University Hospital, Singapore","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100546267","phase-1-dose-escalation-trial-of-mesenchymal-stromal-cells-in-patients-with-medical-xerostomia-100546267","NCT06392711","Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia","UW23129: A Phase I Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia","Inclusion Criteria:\n\n* Xerostomia, defined as an unstimulated salivary flow \\\u003C1.2 mL in 5 minutes documented at any time following xerostomia diagnosis and prior to enrollment\n* Xerostomia not resulting from radiotherapy (medical xerostomia)\n* ≥ 18 years of age, ≤ 90 years of age\n* Karnofsky performance status ≥ 70, patient eligible for bone marrow aspirate with wakeful anesthesia\n* Willing and able to give informed consent\n* Radiographically confirmed bilateral submandibular glands\n* If female of childbearing potential, negative pregnancy test\n* Males and females of childbearing potential willing to use acceptable contraception\n* Laboratory Values (within 28 calendar days of enrollment):\n\n  * Hgb ≥ 9 g\u002FdL (5.58 mmol\u002FL)\n  * Platelets ≥ 100,000\u002FµL\n  * ANC ≥ 1000\u002FµL\n  * Lymphocytes ≥ 800\u002FµL\n  * PT\u002FINR and PTT within normal limits based on age\u002Fsex\n\nExclusion Criteria:\n\n* Patients with one submandibular gland\n* Sialolithiasis\n* Poorly-controlled diabetes mellitus (HbA1c ≥ 7%)\n* Patients who initiated any diuretic therapy before developing dry mouth symptoms and are still on diuretic therapy and the referring provider believes the dryness symptoms are driven by diuretic use\n* Untreated oral candidiasis based on physical exam at enrollment\n* Malignancy within the last 2 years (except adequately treated stage I lung cancer, low risk prostate cancer that has been treated or is undergoing active surveillance, adequately treated non-melanoma skin cancer, adequately treated DCIS, or adequately treated stage I cervical cancer)\n* For patients on immunosuppressive therapy, must be on stable dose of immunosuppressive therapy for at least 2 months, allowing for dose adjustments for blood levels of drugs\n* Transfusion dependency\n* Life expectancy ≤ 6 months as determined by the investigator\n* Use of investigational drugs, biologics, or devices within 30 calendar days prior to enrollment\n* Pregnant or lactating women or those who plan to become pregnant during the study\n* Not suitable for study participation due to other reasons at discretion of investigators.\n* Enrollment in another clinical study possibly interfering with the endpoints of this study","18 Years","90 Years",{"count":57,"type":20},36,[59],"PHASE1","The goal of this clinical trial is to evaluate the safety and tolerability of injecting certain cells produced in bone marrow called mesenchymal stromal cells (MSCs) into salivary glands. The main question it aims to answer is whether injection of MSCs into salivary glands results in any improvement in dry mouth.\n\nParticipants will:\n\n* have bone marrow collected using a needle\n* undergo a salivary gland ultrasound\n* complete questionnaires\n* receive an injection of the bone marrow cells into a salivary gland",[26,62,63],"Graft-versus-host-disease","Sjogren's Disease","RECRUITING","2026-06-17",{"date":67,"type":38},"2026-06-22",{"date":69,"type":38},"2024-10-04",{"date":71,"type":20},"2028-11",{"name":73,"class":45},"University of Wisconsin, Madison",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":46},"100591778","effect-of-enzymatic-containing-mouth-spray-oral7-on-xerostomia-symptoms-salivary-flow-rate-and-oral-health-related-quality-of-life-in-older-patients-100591778","NCT06984848","Effect of Enzymatic-Containing Mouth Spray (Oral7®) on Xerostomia Symptoms, Salivary Flow Rate, and Oral Health-Related Quality of Life in Older Patients","Effect of Enzymatic-Containing Mouth Spray (Oral7®) on Xerostomia Symptoms, Salivary Flow Rate, and Oral Health-Related Quality of Life in Older Patients: A Randomised Placebo-Control Trial","Inclusion Criteria:\n\n* Aged 60 years and above\n* Patients with often or always having dry mouth\u002Fxerostomia by asking single-item xerostomia question: \"How often does your mouth feel dry?\" (Adakah mulut anda sering merasakan kekeringan?). The response options were \"Never (Tidak Pernah),\" \"Sometimes (Kadang-kadang),\" \"Often (Kerap),\" or \"Always (Sentiasa\u002FSepanjang masa).\"\n* Patients who are taking nutrition orally\n* Patients who are able to speak\n* Patients who are physically fit to take oral spray on their own.\n\nExclusion Criteria:\n\n* • Patients on salivary substitutes for the past one week\n\n  * Oral condition that required immediate attention such as mucosal or gingival bleeding, orofacial swelling, oral pain and oral ulcer.\n  * Patients who are deaf and mute\n  * Those with mental disabilities or documented cognitive deficits that would impair their ability to answer questions independently.","60 Years",{"count":83,"type":20},100,[23],"Background: Xerostomia, or dry mouth, is a prevalent condition among older adults and has significant implications for oral and systemic health. It is associated with impaired chewing, swallowing, and speech, and increases the risk of oral infections, dental caries, and gum disease. Xerostomia may also contribute to malnutrition and aspiration pneumonia.\n\nObjective: This study aims to evaluate the effectiveness of an enzymatic-containing mouth spray (Oral7®) on xerostomia symptoms, unstimulated salivary flow rate, and oral health-related quality of life (OHRQoL) in older patients with xerostomia.\n\nMethods: A single-center, randomized, double-blind, placebo-controlled trial will be conducted at Hospital Universiti Sains Malaysia from August 2025 to July 2026. Eligible participants aged 60 and above with self-reported xerostomia will be randomly assigned to receive either Oral7® Mouth Spray or a placebo spray for four weeks. The primary outcome is the mean change in Summated Xerostomia Inventory (SXI) scores between groups from baseline to post-intervention. Secondary outcomes include changes in unstimulated salivary flow rate using the sialometry technique and OHRQoL measured by the Geriatric Oral Health Assessment Index (GOHAI) at baseline and three months post-intervention. Data will be analyzed using SPSS version 29.\n\nConclusion: This trial will provide evidence on the efficacy of Oral7® Mouth Spray in alleviating xerostomia symptoms and improving salivary function and oral health-related quality of life in older adults, potentially guiding future clinical management of this condition.",[26,87],"Geriatric",[26,89,90,91],"dry mouth","geriatric","older patient","2026-05-20",{"date":94,"type":38},"2026-05-22",{"date":96,"type":38},"2025-09-18",{"date":98,"type":20},"2027-05-01",{"name":100,"class":101},"ZAINAB MAT YUDIN","INDUSTRY",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":46},"100640339","does-hyaluronic-acid-help-relieve-dry-mouth-100640339","NCT07594184","Does Hyaluronic Acid Help Relieve Dry Mouth?","Efficacy of Submucosal Hyaluronic Acid Infiltration in Improving the Sensation of Dry Mouth in Patients With Xerostomia: A Double-Blind Randomized Clinical Trial.","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Patients reporting symptoms compatible with xerostomia for at least one year\n* Patients who agree to cooperate in the study, comply with the follow-up plan, and sign the informed consent\n\nExclusion Criteria:\n\n* Underage patients\n* Pregnant patients\n* Patients on antiplatelet or anticoagulant therapy\n* Patients with a history of adverse reactions to hyaluronic acid infiltration\n* Patients with active infectious diseases in the oral cavity\n* Immunocompromised patients\n* Patients with other active diseases affecting the oral mucosa\n* Patients with uncontrolled autoimmune diseases\n* Patients allergic to lidocaine and\u002For mepivacaine\n* Patients undergoing active chemotherapy and\u002For radiotherapy for head and neck\n* Non-cooperative patients (e.g., psychomotor dysfunctions and behavioral disorders)",{"count":110,"type":20},40,[23],"The goal of this clinical trial is to learn if hyaluronic acid infiltration helps relieve dry mouth symptoms in adults with xerostomia. It will also assess the safety and duration of the treatment's effects.\n\nThe main questions it aims to answer are:\n\n1. Does hyaluronic acid improve the sensation of dry mouth?\n2. What side effects may occur after treatment?\n3. How long does the effect of the treatment last?\n4. Are there changes in salivary flow and pH after treatment?\n\nResearchers will compare hyaluronic acid to a placebo (a look-alike substance with no active ingredient) to determine its effectiveness.\n\nParticipants will:\n\nReceive submucosal injection of either hyaluronic acid or placebo Visit the clinic once a month for 6 months for follow-up evaluations Not be required to perform any tasks at home",[26],"2026-05-13",{"date":116,"type":38},"2026-05-18",{"date":118,"type":38},"2025-11-11",{"date":120,"type":20},"2026-12",{"name":122,"class":45},"University of Barcelona",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":149,"locationsCount":46},"100447451","photobiomodulation-therapy-plus-m-health-in-head-and-neck-cancer-patients-laxer-study-100447451","NCT05106608","Photobiomodulation Therapy Plus M-health in Head and Neck Cancer Patients: LAXER Study","Photobiomodulation Therapy With M-health Tool for the Management of Oral Health and Quality of Life in Head and Neck Cancer Patients: LAXER Study","LAXER","Patients will be included in the study if they meet the following inclusion criteria:\n\n* men or women aged 18 years or older and were diagnosed with HNC.\n* chronic xerostomia.\n* received RT in the parotid, submandibular and\u002For sublingual salivary glands.\n* grade 3 oral dryness according to the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE).\n* medical treatment completed and in complete remission.\n* received medical clearance for participation in this study.\n* at least one month passed since the end of RT to avoid the possible presence of oral mucositis and\u002For radiodermatitis, which limits adherence to treatment and maximum 36 months.\n* no history of drugs\u002Fdevices\u002Fproducts (pilocarpine, cevimeline, amifostine, oral devices, humidifiers, or herbs) to prevent or treat xerostomia prior to study inclusion or no change in their use (no change in type or dose) for two months prior to study inclusion.\n* and able to access mobile applications or living with someone who has this ability.\n\nThe exclusion criteria will be as follows:\n\n* patients with metastases.\n* a score \\\u003C60 on the Karnofsky Performance Status Scale.\n* contraindications to receiving PBM therapy (e.g., cardiac arrhythmias, pacemakers, photosensitivity, drugs with photosensitizing action, and pregnancy).\n* other comorbidities such as diabetes and polypharmacy.\n* and retraction of the declaration of consent.",{"count":132,"type":20},60,[23],"The Photobiomodulation therapy could have positive effects on quality of life and oral health in head and neck cancer survivors post-radiotherapy. The improvement in quality of life will be maintained after a follow-up period.",[136,137,26],"Head and Neck Cancer","Head and Neck Neoplasms",[139,140,26,141,142],"Quality of Life","Neoplasms","Low-Level Light Therapy","Telemedicine","2025-12-30",{"date":145,"type":38},"2026-01-05",{"date":147,"type":38},"2022-07-13",{"date":120,"type":20},{"name":150,"class":45},"Universidad de Granada",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":46},"100392638","phase-1-d-limonene-radiation-platinumbasedchemo-for-xerostomia-prevention-in-locallyadvanced-hnscc-100392638","NCT04392622","d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC","A Phase I Study of d-Limonene With Concurrent Radiation and Platinum Based Chemotherapy for Xerostomia Prevention in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)","Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of advanced loco regional squamous cell carcinoma of the nasopharynx (AJCC v8 Stage II IV); oropharynx (AJCC v8 Stage I III for HPV+ cancer, excluding T1 2N0; AJCC v8 Stage III IV for Human papillomavirus (HPV) negative cancer); larynx (AJCC v8 Stage III to IV); or hypopharynx (AJCC v8 Stage III to IV), scheduled to undergo chemoradiation. Patients with squamous cell carcinoma of the head and neck from an unknown primary site with involved nodes (N1 to 3) also qualify.\n* Scheduled to received definitive RT with concurrent platinum based chemotherapy at Stanford\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 1\n* Must be able to swallow d limonene gelcaps at the time of enrollment.\n* Adequate hepatic function within 2 weeks prior to registration defined as follows: Bilirubin ≤ 2 mg\u002FdL; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\\u003C 3 times the upper limit of normal\n* Adequate hematologic function within 2 weeks prior to registration defined as follows:\n\n  * Absolute neutrophil count (ANC): ≥ 1,500\u002Fmm3\n  * Platelets: ≥ 100,000\u002Fmm3\n  * Hemoglobin: ≥ 8.0 g\u002FdL (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g\u002FdL is acceptable).\n* Adequate renal function defined as follows:\n\nSerum creatinine ≤ 1.5 mg\u002FdL within 2 weeks prior to registration or creatinine clearance (CC) ≥ 50 mL\u002Fmin within 2 weeks prior to registration determined by 24 hour collection or estimated by Cockcroft Gault formula:\n\nCCr male = \\[(140 - age) x (wt in kg)\\] \\[(Serum Cr mg\u002FdL) x (72)\\] CCr female = 0.85 x (CrCl male)\n\n* Negative serum pregnancy test within 2 weeks prior to registration and agreement to use a birth control method during the entire duration of d limonene treatment for women of childbearing potential\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* History of allergic reactions attributed to citrus fruits\n* Pregnant or lactating",{"count":110,"type":20},[59],"This study explores the safety of d-limonene, a commercially-available dietary supplement (food) as a potential therapeutic for the severe dry mouth (xerostomia) experienced by patients with head and neck cancer as a side effect of their anti-cancer treatment.",[26],"2025-07-16",{"date":164,"type":38},"2025-07-20",{"date":166,"type":38},"2021-02-15",{"date":168,"type":20},"2028-05-15",{"name":170,"class":45},"Stanford University",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":21,"phases":180,"briefSummary":181,"conditions":182,"keywords":183,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":46},"100551864","acupressure-on-xerostomia-in-head-and-neck-cancer-patients-100551864","NCT06465628","Acupressure on Xerostomia in Head and Neck Cancer Patients","Effect of Self-administered Acupressure for Improving Xerostomia in Head and Neck Cancer Patients: a Randomized Controlled Trial","Inclusion Criteria:\n\n* age ≥18 years;\n* able to give informed consent;\n* diagnosed with head and neck cancer (cancers in the head and neck region, e.g. oral cancer, nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, sinus cancer, salivary gland cancer);\n* completed radiation therapy or chemoradiotherapy for at least 2 weeks;\n* complains of xerostomia after the treatment;\n* able to communicate in Cantonese or Mandarin.\n\nExclusion Criteria:\n\n* history of xerostomia prior to head and neck cancer treatment (e.g., Sjögren Syndrome);\n* practiced acupressure or received acupuncture in the last 3 months;\n* having contraindications to acupressure, e.g. blood system disease (e.g., leukemia); pregnancy; lactating; upper or lower extremity deformities; infection or injuries at the acupoints.\n\nThose who are taking medications\u002Falternative substances to treat xerostomia on a fixed dosage regimen in the past one month will not be excluded.\n\n\\-",{"count":179,"type":20},126,[23],"This is a randomized controlled trial aimed to1) examine the effect of a self-administered acupressure intervention on head and neck cancer patients with xerostomia (primary outcome) relative to oral health education control; 2) examine the effect of self-administered acupressure on secondary outcomes, including quality of life and severity of symptoms of head and neck cancer patients; 3) evaluate patients' expectancy of acupressure; 4) explore the acceptability of self-administered acupressure for head and neck cancer patients with xerostomia.\n\nHypothesis: self-administered acupressure has better effect on xerostomia for head and neck cancer patients comparing to oral health education. Acupressure will also benefit head and neck cancer patients on quality of life and severity of symptoms. Head and neck cancer patients may have good acceptability of self-administered acupressure.",[136,26],[184,26,185,186],"Self-administered acupressure","Head and neck cancer","Quality of life","2025-05-26",{"date":189,"type":38},"2025-05-28",{"date":191,"type":38},"2024-12-01",{"date":193,"type":20},"2027-03-31",{"name":195,"class":45},"The University of Hong Kong",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":203,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":21,"phases":206,"briefSummary":207,"conditions":208,"keywords":214,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":46},"100461493","efficacy-of-the-vacucis-candida-autovaccine-100461493","NCT05289375","Efficacy of the Vacucis Candida® Autovaccine","Efficacy of the Vacucis Candida® Autovaccine in the Management of Chronic Oral Candidiasis. Randomized Triple-blind Randomized Clinical Trial.","Inclusion Criteria:\n\n* Patients with a history of RT in the head and neck region that directly or indirectly involves any of the jaws.\n* Adult patients\n* Hemodynamically stable patients without contraindications to receive an autovaccine (see exclusion)\n* Patients with a stable oncological situation without active tumor\n* Patients who present candidiasis demonstrated by clinical examination (signs and symptoms of candidiasis) and microbiological (culture).\n\nExclusion Criteria:\n\n* Minor patients\n* Pregnant patients\n* Patients with an unstable medical situation, both from a hemodynamic and oncological point of view (advanced tumors with metastases, recurrences or inoperable tumors)\n* Patients undergoing treatment with CT that involves an affectation of the immune system\n* Patient under treatment with antifungals for mycoses of any origin\n* Allergy to the active substance or to any of the other components of Vacucis.\n* Serious disorders of the immune system.\n* Diseases that severely affect immunity.\n* Presence of fever.\n* People with allergies to yeasts\n* People with allergy to chloramphenicol\n* Patients treated with MAOIs (monoamine oxidase inhibitors)",true,{"count":205,"type":20},46,[23],"Introduction: Oral candidiasis is an infectious disease caused by the growth of Candida colonies and their penetration into oral tissues when physical barriers and host defenses are weakened. It constitutes one of the most common pathologies within the field covered by Dentistry. Candida infections are found in at least 80% of AIDS patients and in a third of HIV infection cases. Systemic diseases such as diabetes and a wide pharmacological arsenal to which the general population is subjected, are other causes of the increase in the prevalence of this disease. In addition, the high prevalence of oral sequelae (hyposialia) in the population over 65 years of age, due to the specific characteristics of this age group, such as multiple pathologies and drug use, explains the presence of this disease in this segment. of the population One of the great difficulties for the study of this disease is the diversity of predisposing factors, which do nothing but throw greater confusion into the results of the different works.\n\nObjective: To evaluate the reduction\u002Fsuppression of signs and symptoms of oral candidiasis in patients treated with head and neck RT, users of Vacucis or Placebo.\n\nMaterial and method: Patients will receive information regarding the trial and, if they meet the inclusion criteria and agree to participate in it, they will sign the informed consent. All patients will be informed following the usual care practice of the characteristics of their candidiasis infection as well as the possibilities and alternatives of treatment and their respective efficacy.\n\nA descriptive analysis of the sample in terms of prevalence will be carried out. Categorical variables will be described as frequency and percentage and continuous variables as mean and standard deviation or median and interquartile range depending on their adjustment to normality, which will be calculated with the Kolmogorov-Smirnov test. To study the effect of the vaccine on the evolution of candidiasis, the Chi-square test, Student's t test or the non-parametric Mann-Whitney test will be used. The association of prevalence with CFU in both groups will be analyzed using the ANOVA test. Those values of p \\\u003C 0.05 will be considered significant.",[209,210,211,212,213,26],"Oral Candidiasis","Oral Candidiasis Recurrent","Radiotherapy; Complications","Candida Albicans Infection","Microbial Colonization",[215],"oral candidiasis","2024-10-15",{"date":218,"type":38},"2024-10-17",{"date":220,"type":20},"2025-04-30",{"date":222,"type":20},"2027-12-31",{"name":224,"class":45},"University of Santiago de Compostela",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":233,"phases":4,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":46},"100538166","an-investigation-into-taste-problems-associated-with-xerostomia-in-patients-with-advanced-cancer-100538166","NCT06287294","An Investigation Into Taste Problems Associated With Xerostomia in Patients With Advanced Cancer","Inclusion Criteria:\n\n* 18 years of age\n* Diagnosis of locally advanced or metastatic cancer\n* Referred to palliative care\u002Foncology services\n* Dry mouth rated 'moderate' or worse over previous 2-week period\n* Taste problems rated 'moderate' or worse over previous 2-week period\n* Good understanding of English\n\nExclusion Criteria:\n\n* Cognitive impairment (unable to provide consent \u002F complete questionnaire)\n* Dry mouth precedes cancer diagnosis.\n* Taste problems precedes cancer diagnosis.\n* Head and neck surgery\n* Head and neck radiotherapy\n* Salivary gland disorders (e.g., Sjogren's Syndrome)\n* In the 'Deteriorating' or 'Terminal' Phase of illness",{"count":232,"type":20},120,"OBSERVATIONAL","Taste problems and xerostomia (dry mouth) are common among patients with advanced cancer. These symptoms can affect the pleasure of eating and drinking, reduce dietary intake, cause low mood, and a lower quality of life. This study will explore the relationship between dry mouth and taste problems in patients with advanced cancer.",[236,26,140],"Taste, Altered","2024-09-05",{"date":239,"type":38},"2024-09-19",{"date":241,"type":38},"2023-08-30",{"date":243,"type":20},"2025-12-31",{"name":245,"class":45},"Our Lady's Hospice and Care Services",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":233,"phases":4,"briefSummary":256,"conditions":257,"keywords":260,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":4},"100556886","diagnostic-interest-of-the-buccal-schirmer-test-in-xerostomia-during-sjgrens-syndrome-xerodiag-100556886","NCT06530940","Diagnostic Interest of the Buccal Schirmer Test in Xerostomia During Sjögren's Syndrome: XERODIAG","XERODIAG","Inclusion Criteria:\n\n* Included patients meet the following criteria:\n* age over 18 years\n* diagnosis of Sjogren's syndrome meeting the ACR\u002FEULAR 2016 criteria.\n\nExclusion Criteria:\n\n* These include:\n* Cognitive or dementia disorders\n* Pregnancy","100 Years",{"count":255,"type":20},180,"Xerostomia is a common and very bothersome manifestation that impairs the quality of life in Sjogren's syndrome. Its diagnosis mainly relies on the measurement of salivary flow (SF). Performing this test is unpleasant for the patient, lacks precision, can be influenced by certain conditions, and requires good patient cooperation. Other alternatives such as the buccal Schirmer test can be used. The aim of this study is to demonstrate the non-inferiority of the buccal Schirmer test compared to SF measurement. This is a diagnostic study comparing a group of patients (n=90) with Sjogren's syndrome (SS) and normal SF (≥0.1 ml\u002Fminute) to a group of patients with SS and decreased SF (\\\u003C0.1 ml\u002Fminute).",[258,26,259],"Sjogren's Syndrome","Diagnosis",[261,262,263,264],"xerostomia","sjogren's syndrom","salivary flow","oral schirmer test","2024-07-31",{"date":267,"type":38},"2024-08-02",{"date":269,"type":20},"2024-08-19",{"date":271,"type":20},"2024-12-31",{"name":273,"class":45},"University Tunis El Manar",{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":21,"phases":283,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":290,"leadSponsor":292,"locationsCount":4},"100552679","artificial-saliva-containing-cumin-and-ginger-extract-in-hemodialysis-patients-with-xerostomia-100552679","NCT06476223","Artificial Saliva Containing Cumin and Ginger Extract in Hemodialysis Patients With Xerostomia","Efficacy and Safety of Artificial Saliva Containing Cumin and Ginger Extract in Hemodialysis","Inclusion Criteria:\n\n* Age more than 18 years\n* Hemodialysis patients with xerostomia (saliva flow rate less than 0.2 g\u002Fmin)\n* Hemodialysed history more than 3 months\n* Be willing to participate in the study\n\nExclusion Criteria:\n\n* Patients with sialolith or Sjogren's syndrome\n* Uncontrolled other diseases\n* Using artificial saliva for more than 2 weeks\n* Taking pilocarpine and cevimeline\n* Allergic to ginger, cumin, xylitol, and glycerin\n* Have mucositis\n* Pregnancy or lactation",{"count":282,"type":20},26,[23],"Hemodialysis patients with xerostomia are divided into 2 groups which are group A (start with artificial saliva containing cumin and ginger extract for 2 weeks, free periods 2 weeks, then placebo for 2 weeks) and group B (start with placebo for 2 weeks, free periods 2 weeks, then artificial saliva containing cumin and ginger extract for 2 weeks). Amount of saliva (g\u002Fmin), xerostomia's questionnaire, Increase of saliva score, World Health Organization Oral Mucositis Grading Scale, acid and base of saliva, quality of life's questionnaire will measure before, after using the sample for 7 and 14 days.",[26],"2024-06-28",{"date":288,"type":38},"2024-07-01",{"date":288,"type":20},{"date":291,"type":20},"2025-01-31",{"name":293,"class":45},"Chulalongkorn University",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":21,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":310,"leadSponsor":312,"locationsCount":4},"100506290","artificial-saliva-containing-cumin-and-ginger-extract-in-head-and-neck-cancer-patients-with-xerostomia-100506290","NCT05872464","Artificial Saliva Containing Cumin and Ginger Extract in Head and Neck Cancer Patients With Xerostomia","Efficacy and Safety of Artificial Saliva Containing Cumin and Ginger Extract in Head and Neck Cancer Patients With Xerostomia","Inclusion Criteria:\n\n* Age more than 18 years\n* Head and neck cancer with xerostomia\n* 6 months post radiation\n* Willing to participate in this study\n\nExclusion Criteria:\n\n* Sialolith or Sjogren's syndrome\n* Uncontrolled cancer\n* Using artificial saliva more than 2 weeks\n* Taking Pilocarpine or cevimeline more than 2 weeks\n* Allergic to cumin, ginger, xylitol, and glycerin\n* History of other oral mucosal diseases\n* Pregnancy and lactation",{"count":302,"type":20},52,[23],"The objectives of this study are to evaluate efficacy and safety of artificial saliva containing cumin and ginger extract in head and neck cancer patients with xerostomia.",[26],"2024-06-21",{"date":308,"type":38},"2024-06-24",{"date":288,"type":20},{"date":311,"type":20},"2025-06-30",{"name":293,"class":45},{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":319,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":321,"enrollmentInfo":322,"targetDuration":4,"studyType":21,"phases":324,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":4},"100505131","phase-1-safety-and-potential-effect-of-innovative-cell-based-therapy-using-adipose-derived-stromal-vascular-fraction-in-patients-with-autoimmune-xerostomia-100505131","NCT05857358","Safety and Potential Effect of Innovative Cell-based Therapy Using Adipose-derived Stromal Vascular Fraction in Patients With Autoimmune Xerostomia","Safety and Potential Effect of Innovative Cell-based Therapy Using Adipose-derived Stromal Vascular Fraction in Patients With Autoimmune Xerostomia (XEROCELL)","XEROCELL","Inclusion Criteria:\n\n* Patients from 18 to 65 years.\n* Patients suffering from xerostomia and autoimmune disease including : Gougerot-Sjögren disease according to AC\u002FEULAR criteria and Secondary Gougerot-Sjögren syndrome related to systemic diseases (sclerodermia, rheumatoid arthritis, systemic lupus erythematosus...)\n* Xerostomia visual scale (6-item visual analogue scale questionnaire) for assessment of salivary dysfunction : score ≥ 30\u002F60\n* Informed consent to participate (with signature)\n* Negative β -HCG test and effective contraception for women being able to get pregnant\n* Affiliation to the social security system\n\nExclusion Criteria:\n\n* Medical history of head and neck neoplasia\n* Recent (\\\u003C3 months) medication inducing and aggravating xerostomia : Standard treatment with tricyclic antidepressant and\u002For antipsychotics\n* Body Mass Index \\\u003C 18\n* Active smoking (\\> 5 cigarettes a day)\n* Active infectious disease and\u002For active viral serologies (HIV, HCV, HBV, HTLV I\u002FII, TPHA\u002FVDRL)\n* Coagulation disorders including anticoagulant and antiplatelet treatment\n* Any temporary or definitive contraindication due to any medical or surgical unstable condition\n* Allergy to local anesthesia and\u002For albumin\n* Pregnant or breastfeeding women\n* Adult protected by the law (tutorship and curatorship)\n* Patients already enrolled in another study\n* Patients under 18 years of age\n* Person deprived of liberty\n* Patient non-affiliated to the social security","65 Years",{"count":323,"type":20},18,[59,325],"PHASE2","The main objective of this study is to evaluate the tolerance and safety of autologous adipose-derived stromal vascular fraction injected in accessory salivary glands for treatment of autoimmune xerostomia in terms of adverse reactions through day 14 (D14).",[26],"2023-11-16",{"date":330,"type":38},"2023-11-18",{"date":332,"type":20},"2024-01",{"date":334,"type":20},"2027-08",{"name":336,"class":45},"Assistance Publique Hopitaux De Marseille"]